Newsroom - Best in Class Assays, Reagents and Clinical Lab Services - Invivoscribe

Newsroom – Best in Class Assays, Reagents and Clinical Lab Services2026-05-15T17:11:41-07:00

Newsroom

Newsroom

LATEST PUBLICATIONS

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

2021-02-15T19:48:14-08:00May 6th, 2020|

Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

2021-02-11T21:50:38-08:00May 1st, 2020|

Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status

2021-02-11T21:53:32-08:00April 1st, 2020|

Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications

2021-02-11T21:56:18-08:00March 1st, 2020|

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

2021-02-11T21:58:45-08:00February 6th, 2020|

LATEST PRESS

German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Position

2021-02-26T19:14:37-08:00March 28th, 2016|

Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)

2021-02-26T19:14:49-08:00February 18th, 2016|

Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific

2021-02-26T19:15:19-08:00February 9th, 2016|

Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations

2021-02-26T19:16:48-08:00December 5th, 2015|

CONFERENCES

No conferences from the last year found.